CClinicalTrials.gg
Status unknownNCT04241770TURKMIUpdated Feb 5, 2020

TURKish Acute Myocardial Infarction Registry

An observational study in Acute Myocardial Infarction, sponsored by Turkish Society of Cardiology. Status unknown at 1 site in Turkey. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Turkish Society of Cardiology · Observational

The sponsor has not verified this record recently (last verified Jan 2020), so the status shown — last known as Recruiting — may be out of date.
Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
1,930
Ages
18 Years and older
Sex
All
01

Study summary

There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.

Read the detailed description

Background: There is no up-to-date information regarding presentation, management and clinical course of patients with acute myocardial infarction (MI) in Turkey. TURKMI registry is designed to provide insight to the characteristics, management from symptom onset to the hospital discharge and outcome of patients with acute MI in Turkey.

Methods: TURKMI study, as a nation-wide registry, will be conducted in 50 percutaneous coronary intervention -capable centres selected from each EuroStat NUTS region in Turkey according to their population sampling weight, prioritizing the volume of hospital in each region. All consecutive patients with acute MI admitted to the coronary care units within the 48 hours of symptom onset will be prospectively enrolled during a predefined 2-week period.

The first step of the study has cross-sectional design in which baseline information such as symptoms, risk factors, time periods at each step from symptom onset to revascularization, way of arrival to hospital, biochemical analysis and in-hospital management and outcome will be assessed. The second step has a cohort characteristics in which enrolled patients will be followed-up up to 2 years. Follow-up visits will be conducted at 1st, 6th, 12th and 24th months, and predictors and risk of cardiovascular events, and implementation of guidelines will be assessed as secondary outcomes.

Conclusion: The national TURKMI registry is expected to provide important information to improve the national policy of the diagnosis, management and outcomes of MI in Turkey

02

Conditions studied

  • Acute Myocardial Infarction

Keywords

  • Acute Myocardial Infarction
  • Mortality
  • Registry
  • Turkey
03

In context

Myocardial Infarction

2,744 studies on the registry are indexed under Myocardial Infarction; 418 are open to participants now.

This study's planned enrollment of 1,930 is above the median of 500 across 983 observational studies indexed under Myocardial Infarction.

Browse Myocardial Infarction studies →

Lead sponsor

Turkish Society of Cardiology is the lead sponsor of 4 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Sampling method
Probability sample

Study population

The screened population will consist of all consecutive patients presenting with suspected acute MI in the participating hospitals. Men and women aged ≥18 years will be enrolled if they fulfil the following inclusion criteria;

  1. having hospitalized within 48 hours of onset of symptoms of the index event
  2. had a final (discharge) diagnosis of acute MI either [ST elevation MI (STEMI) or non ST elevation (NSTEMI)] with positive troponin levels, and
  3. having signed an Informed Consent. Patients unwilling or unable to consent will be excluded. To facilitate consecutive enrolment, all patients hospitalized at each participating site with acute MI will be recruited consecutively during the same 2 consecutive weeks (15 days).

Inclusion criteria

  1. having hospitalized within 48 hours of onset of symptoms of the index event
  2. had a final (discharge) diagnosis of acute MI either [ST elevation MI (STEMI) or non ST elevation (NSTEMI)] with positive troponin levels, and
  3. having signed an Informed Consent. To facilitate consecutive enrolment, all patients hospitalized at each participating site with acute MI will be recruited consecutively during the same 2 consecutive weeks (15 days).

Exclusion criteria

Exclusion Criteria:

  1. Patients unwilling or unable to consent will be excluded.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
1,930 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • Otherno intervention

    no intervention

06

What researchers measure

Primary outcomes

  1. Number of participants died

    all cause of death including cardiovascular death

    Time frame: from enrollment till to 2 years follow up

Secondary outcomes

  1. Number of participants developed cardiovascular morbidity

    non-fatal MI, stroke, coronary or peripheral revascularization, emergency department visit due to chest pain or dyspnea, hospitalization for heart failure will be assessed at 1st month and then at every 6 month intervals until the second year.

    Time frame: from enrollment till to 2 years follow up

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04241770
Lead sponsor
Turkish Society of Cardiology
Collaborators
AstraZeneca
Responsible party
Sponsor
First posted
Jan 27, 2020
Start date
Nov 1, 2018
Primary completion
Dec 1, 2022 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Feb 5, 2020

Study contacts

MERAL KAYIKCIOGLU, Prof
Contact
meral.kayikcioglu@gmail.com
+905324123489
MUSTAFA K EROL, Prof
Contact
erolmk@gmail.com
MUSTAFA K EROL, prof
study director · Istanbul Private Sisli International Kolan Hospital,
MERAL KAYIKCIOGLU, prof
principal investigator · Ege University School of Medicine Department of Cardiology
MUSTAFa KILICKAP, prof
principal investigator · ANKARA University School of Medicine Department of Cardiology

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion